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Abstract
Background: Cyclin D1 (CCND1) plays a vital role in cancer cell cycle progression. Numerous epidemiological studies have
evaluated the association between the CCND1 G870A polymorphism and the risk of colorectal cancer. However, these
studies have yielded conflicting results. To derive a more precise estimation of this association, we conducted a meta-
analysis and systematic review.
Methodology/Principal Findings: A comprehensive search was conducted to identify eligible studies of the CCND1 G870A
polymorphism and colorectal cancer risk. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were derived from a
fixed effect or random effect model. We applied a grading system (Venice criteria) that assessed the epidemiological
strength of the association. A total of 22 publications that included 6157 cases and 8198 controls were identified. We found
that the CCND1 G870A polymorphism was significantly associated with overall colorectal cancer risk (homozygote genetic
model: OR=1.130, 95% CI=1.023–1.248, P=0.016; heterozygote genetic model: OR=1.124, 95% CI=1.030–1.226, P=0.009;
dominant genetic model: OR=1.127, 95% CI=1.037–1.224, P=0.005). After further stratified analyses, the increased risk was
observed only in the subgroups of hospital-based studies, PCR-RFLP genotyping methods, sporadic colorectal cancer, and
Caucasian ethnicity.
Conclusions: The available evidence demonstrates that the CCND1 870A allele might be a low-penetrant risk factor for
colorectal cancer.
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Introduction
Colorectal cancer (CRC) is the second most common type of
cancer in women and the third most common type in men in the
United States and Europe [1,2]. The multistep carcinogenesis of
the adenoma-carcinoma sequence is determined by caretaker
molecular pathways, and this conventional theory is also thought
to describe colorectal oncogenesis [3,4]. However, it is now
commonly accepted that the pathogenesis of CRC involves the
multi-factorial interactions of environmental triggers and genetic
susceptibility [5]. A recent study have revealed that approximately
35% of CRC cases can be attributed to inherited genetic
susceptibility [5].
The adenine-to-guanine (A/G) substitution at nucleotide 870
(CCND1 G870A polymorphism, rs603965) and excessive cyclin D1
activity are common in numerous human tumors, including breast
cancer, lung cancer, head and neck cancers, gastric cancer,
gynecological cancers, blood-related cancers, and CRC [6,7].
Although various studies have linked the CCND1 G870A
polymorphism to increased CRC risk, the results remain
controversial. To further investigate the combined effect of the
CCND1 G870A polymorphism on CRC susceptibility, we
performed a meta-analysis and systematic review.
Methods
Identification and Eligibility of Relevant Studies
All published literature investigating an association between the
CCND1 G870A polymorphism and colorectal cancer risk were
eligible. We searched for studies using the PubMed database up to
October 2011. The relevant search terms ‘‘G870A’’, ‘‘A870G’’,
‘‘CCND1’’, ‘‘cyclin D1’’, ‘‘polymorphism’’, ’’cancer’’, ‘‘colorectal’’,
‘‘colonic’’, ‘‘colon’’, ‘‘rectal’’, ‘‘rectum’’, and ‘‘humans’’ were used.
Both free text and a MeSH search for keywords were employed.
We also manually searched the reference lists in selected articles
and the abstracts published at major international conferences.
Abstracts that were not written in English were excluded. All the
studies met the following criteria: (1) the CCND1 G870A
polymorphism was determined; (2) the outcome had to be
colorectal cancer in humans. The major exclusion criteria were
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not a case-control design; (4) insufficient data were reported as
cyclin D1 expression levels were provided without genotype data;
(5) overlapping data and data superseded by the latest reports.
Data Extraction
Data were extracted independently and crosschecked against
the research consensus. The following variables were recorded: the
first author’s last name; publication year; region/country where
the study was performed; participant gender; ethnicity (included
Caucasian, Asian and Mixed) of the study population; epidemi-
ological type of colorectal cancer (included hereditary nonpolyp-
osis colorectal cancer (HNPCC), sporadic colorectal cancer
(sCRC), and sporadic colonic cancer (sCC)); histopathological
subgroup information if known (included Dukes’ stage (A/B and
C/D) and degree of differentiation (well/moderate, moderate and
poor)); control source (family-based study (FB), population-based
study (PB), and hospital-based study (HB)); genotyping method
(polymerase chain reaction (PCR) single-stranded conformation
polymorphism (PCR-SSCP), PCR restriction fragment length
polymorphism (PCR-RFLP), high-performance liquid chromatog-
raphy (HPLC), TaqMan PCR, and DNA sequencing); sample size
(total cases and controls as well as the numbers of cases and
controls with G/G, G/A, and A/A genotypes); and the P value of
the Hardy-Weinberg equilibrium in the control group. Only the
latest studies were included when the data sets overlapped or were
duplicated. The primary authors were contacted to provide
additional information when necessary. Study identification and
data extraction were conducted independently by three investiga-
tors and checked for accuracy by one author.
Statistical Analysis
Dichotomous variables were pooled using an odds ratio (OR).
The summary OR was replaced by the risk difference (RD) if one
of the studies reported no events in either the case group or the
control group.
The wild type G/G genotype was considered as a reference.
Pooled effects were calculated for a homozygote comparison
model (A/A vs. G/G), a heterozygote comparison model (G/A vs.
G/G), a dominant model (G/A+A/A vs. G/G), and a recessive
model (A/A vs. G/G+G/A).
The statistical heterogeneity between included studies was
determined using the chi-square-based Q-test [8,9]. According to
the Higgins’ I
2 statistic, heterogeneity was defined as low or
moderate if less than 50% and high if greater than 50% [8]. A
fixed effect model was applied using the Mantel-Haenszel method
for low or moderate statistical heterogeneous studies [10]. A
random effect model, which assumed that the studies involved
came from a random sample of a hypothetical population of
studies that took into account heterogeneity, was used when
heterogeneity was high [11]. A Galbraith plot was created to
graphically assess the extent of heterogeneity between studies from
the current meta-analysis [12,13]. A L’Abbe ´ plot was used for the
additionally assessment of colorectal cancer risk [14,15]. The
Hardy-Weinberg equilibrium (HWE) was determined using
the chi-square test in the control groups [16].
Sensitivity analyses were conducted either by replacing a value
of effect with another or removing individual studies from the data
set. Sensitivity analyses were also performed by excluding studies
in which the genotype frequencies in the controls significantly
deviated from the HWE. We conducted subgroup analyses of the
study design, cancer type, cancer location, ethnicity, Dukes’ stage,
degree of differentiation, gender and genotyping method to
investigate potential sources of heterogeneity.
Publication bias among the included studies was assessed
graphically using a Begg’s funnel plot [17]. Additionally,
publication bias was also evaluated statistically with an Egger’s
test [18].
The study confidence interval (CI) was established at 95%.
Two-tailed P values of less than 0.05 were considered statistically
significant. All statistical analyses were performed using the
STATA version 11.0 software (Stata Corporation, College Station,
TX).
Assessment of Cumulative Evidence
The Venice criteria [19] were developed by the Human
Genome Epidemiology Network (HuGENet) Working Group to
assess the cumulative epidemiological strength of genetic associ-
ation studies; these same criteria were applied in this study.
Following the Venice criteria, our meta-analysis was graded based
on three categories: (1) the amount of evidence (sample sizes of
cases and controls that were greater than 1000, 100–1000, or less
than 100 were assigned a grade of A, B, or C, respectively); (2) the
extent of replication (a Higgins’ I
2 statistic [8] that was less than
25%, 25% – 50% or greater than 50% was assigned a grade of A,
B, or C, respectively); (3) protection from bias (a grade of A was
assigned if there was no observable bias, a grade of B was assigned
if bias could be present or could explain the presence of the
association; a grade of C was assigned if bias was considerable and
had an effect even the presence or absence of the association).
Results
Characteristics of the Studies
Through literature search and selection, a total of 22 publications
[20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,-
41] including 6157 cases and 8198 controls comparing the CCND1
G870A polymorphism and colorectal cancer susceptibility were
identified based on MOOSE (Meta-analysis Of Observational
Studies in Epidemiology) guidelines [42]. Two studies [24,35]
investigated both HNPCC and sCRC, and the genotype frequen-
cies were therefore separated into three types: Mixed, HNPCC, and
sCRC. One article [26] mentioned two independent populations
(Asians and Caucasians), and the study was thus treated as three
separate estimates: Mixed, Asians, and Caucasians. A flow chart of
the inclusion and exclusion criteria is presented in Figure 1.
Five articles [20,26,34,37,39] showed mixed or missing ethnicity
data. Nine studies [24,30,32,33,34,35,37,40,41] showed mixed types of
cancer data. Of the 22 included studies, 2 were family-based [20,22],
11 were population-based [21,23,24,26,28,31,32,33,37,38,40], and 9
were hospital-based [25,27,29,30,34,35,36,39,41]. Multiple genotyp-
ing methods were employed in the studies and included PCR-RFLP,
PCR-SSCP, HLC, TaqMan PCR, and DNA sequencing. The
distribution of genotypes in the controls of all studies was consistent
with Hardy-Weinberg equilibrium except in one study [29].
Characteristics of the studies included are summarized in Table 1.
Heterogeneity Analysis
The genotype data in the 22 studies were homogenous for the
heterozygote genetic model (G/A vs. G/G: Q-test=23.65,
P=0.310, I
2=11.20) and the dominant genetic model (G/A+A/
A vs. G/G: Q-test=27.93, P=0.142, I
2=24.80), but heteroge-
neity was significant for the homozygote genetic model (A/A vs.
G/G: Q-test=39.53, P=0.008, I
2=46.90) and the recessive
genetic model (A/A vs. G/G+G/A: Q-test=27.93, P=0.142,
I
2=52.70).
Galbraith plot analyses of all included studies were used to
assess the potential sources of heterogeneity. Two studies [20,41]
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comparison model (Figure 2).
Association of the CCND1 G870A Polymorphism with CRC
Susceptibility
The multivariable-adjusted ORs for each study and the OR for
the combination of all the studies are shown in Table 2; these
ORs were used to determine the association of the G870A
polymorphism with CRC susceptibility. A significant association of
the G870A polymorphism with CRC susceptibility was observed
in the homozygote comparison model, the heterozygote compar-
ison model, and the dominant model when all the studies were
considered (A/A vs. G/G: OR=1.130, 95% CI=1.023–1.248,
P=0.016; G/A vs. G/G: OR=1.124, 95% CI=1.030–1.226,
P=0.009; G/A+A/A vs. G/G: OR=1.127, 95% CI=1.037–
1.224, P=0.005), However, the association was not observed in
the recessive genetic model (A/A vs. G/G+G/A: OR=1.067,
95% CI=0.941–1.210, P=0.311).
Stratifying Analyses
We conducted subgroup analyses, and the results are listed in
Table 2. Additionally, the L’Abbe ´ plot was also used to assess the
CRC risk in each group in all included studies (Figure 3).
Significant association of the CCND1 G870A polymorphism
with CRC risk was observed in many subgroup categories,
including subsets of hospital-based studies (A/A vs. G/G:
OR=1.260, 95% CI=1.072–1.482, P=0.005; G/A vs. G/G:
OR=1.249, 95% CI=1.082–1.442, P=0.002; G/A+A/A vs. G/
G: OR=1.252, 95% CI=1.093–1.433, P=0.001), subsets of
sCRC cases (G/A vs. G/G: OR=1.204, 95% CI=1.053–1.376,
P=0.007; G/A+A/A vs. G/G: OR=1.188, 95% CI=1.046–
1.348, P=0.008), subsets of Caucasian ethnicity (G/A vs. G/G:
OR=1.145, 95% CI=1.004–1.306, P=0.043; G/A+A/A vs. G/
G: OR=1.162, 95% CI=1.026–1.316, P=0.018), subsets of
Duke’s stage C/D (A/A vs. G/G: OR=1.275, 95% CI=1.007–
1.613, P=0.043; G/A vs. G/G: OR=1.365, 95% CI=1.097–
1.698, P=0.005), subsets of the well/moderate degree of
differentiation (G/A+A/A vs. G/G: OR=1.337, 95%
CI=1.063–1.682, P=0.013), male subjects (G/A vs. G/G:
OR=1.393, 95% CI=1.073–1.809, P=0.013; G/A+A/A vs.
G/G: OR=1.359, 95% CI=1.080–1.710, P=0.009), and subsets
of the PCR-RFLP genotyping method (A/A vs. G/G:
OR=1.262, 95% CI=1.126–1.415, P,0.001; G/A vs. G/G:
OR=1.190, 95% CI=1.076–1.315, P=0.001; G/A+A/A vs. G/
G: OR=1.216, 95% CI=1.106–1.337, P,0.001). Specifically,
the subgroup of Caucasian ethnicity was associated with 1.3- to
Figure 1. Flow chart of study selection according to MOOSE guidelines [42].
doi:10.1371/journal.pone.0036813.g001
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e368131.5-fold increased risk of sCRC without heterogeneity (A/A vs. G/
G: OR=1.511, 95% CI=1.158–1.972, P=0.002; G/A vs. G/G:
OR=1.307, 95% CI=1.057–1.617, P=0.014; G/A+A/A vs. G/
G: OR=1.369, 95% CI=1.118–1.676, P=0.002) (Table 2).
Sensitivity Analyses
Sensitivity analyses was performed by omitting one study at a
time. This procedure did not influence the pooled value, which
supports the robustness of this current meta-analysis.
Publication Bias Analysis
The Begg’s funnel plot and the Egger’s test (A/A vs. G/G:
P=0.465; G/A vs. G/G: P=0.731; G/A+A/A vs. G/G:
P=0.516; A/A vs. G/G+G/A: P=0.399) showed no evidence
of publication bias (Figure 4).
Assessment of Cumulative Evidence
We applied the Venice criteria [19] to evaluate the overall
evidence of an association between the CCND1 G870A polymor-
phism and colorectal cancer susceptibility. The total sample size
(6157 cases and 8198 controls) in our meta-analysis exceeded
1000. Therefore, we assigned the amount of evidence category an
A grade. Next, we assessed the extent of replication. Our meta-
analysis showed a significantly increased risk of colorectal cancer
in the homozygote genetic model, the heterozygote genetic model
and the dominant genetic model but not in the recessive model in
any category. We observed minimal heterogeneity in the
heterozygote genetic model and the dominant genetic model
and moderate heterogeneity in the heterozygote genetic model.
Therefore, we assigned a B grade for the extent of replication.
Finally, there was no evidence of publication bias in our pooled
data, and most of the included studies were well matched for race,
ethnicity, gender and age. The summary ORs of each genetic
model were greater than 1.15; therefore, bias could not have easily
rendered the observed association. Nevertheless, most studies did
not publish sufficient information about whether the G870A
polymorphism was relevant to other polymorphisms or other
candidate genes. Therefore, the Venice criterion of protection
from bias was given a B grade. The overall grade of the Venice
criteria for our data was ‘‘ABB’’, which is consistent with moderate
evidence demonstrating the linkage between the G870A polymor-
phism and colorectal cancer risk.
Discussion
Cell cycle regulation plays an important role in the evolution of
cancer by influencing cell proliferation, differentiation and
apoptosis [43]. It has been demonstrated in all eukaryotic
organisms that the transition from the G1 phase to the S phase
of the cell cycle is controlled by sequential activation of cyclin/
cyclin-dependent kinase (Cdk) complexes [44]. The cyclin D1
locus (also called CCND1 or PRAD1, located on 11q13) consists of
five exons and four introns and encodes cyclin D, a key regulatory
protein promoting the transition through the restriction point in
the G1 phase [45]. Over 250 single nucleotide polymorphisms
(SNP) spanning CCND1 have been identified and cataloged in
public SNP databases (dbSNP: www.ncbi.nlm.nih.gov/SNP/;
HapMap: www.hapmap.org). Of the polymorphisms identified,
the common adenine-to-guanine (A/G) substitution at nucleotide
870 in the conserved splice donor region of exon 4 has received
the most investigation [6]. Normally, the G870 allele creates an
optimal splice donor site and results in a well-described transcript
for cyclin D1, termed cyclin D1a; however, the CCND1 G870A
Figure 2. Galbraith plot [12] analysis of the amount of heterogeneity from all the included studies (AA vs. GG). The y-axis shows the
ratio of the log OR to its standard error (SE), and the x-axis shows the reciprocal of the SE. Each study is represented by the name of the first author. A
regression line runs centrally through the name. At a 2 standard deviation distance parallel to the regression line, the 2 lines create an interval.
Studies lacking in heterogeneity would lie within the 95% confidence interval (positioned 2 units above and below the central regression line).
doi:10.1371/journal.pone.0036813.g002
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36813polymorphism at the boundary of exon 4 and intron 4 affects
alternative splicing and results in an variant transcript for cyclin
D1, termed cyclin D1b, which lacks exon 5 [6,46,47]. Therefore,
cyclin D1b is homologous to cyclin D1a but lacks two regulatory
motifs, the point estimation by sequential testing (PEST) domain
and the threonine 286 phosphorylation site for glycogen synthase
kinase 3ß, both of which are crucial in preventing the
overexpression of cyclin D1 [6,46,47]. Excessive cyclin D1
activates CDK4/cyclin D1 complexes and initiates the phosphor-
ylation of RB, which disrupts RB-mediated transcriptional
repression of E2F and facilitates cell cycle progression [48,49].
The current meta-analysis and systematic review summarizes
the results from 22 case-control studies on the association of the
CCND1 G870A polymorphism with CRC risk. A total of 6157
cases and 8198 controls were included. Based on the Venice
criteria, the results indicated that the G/A or A/A genotype of
CCND1 SNP rs603965 was significantly associated with an
increased risk of CRC. Additionally, we found no significant risk
of CRC associated with the CCND1 G870A polymorphism for the
recessive model in any category, indirectly suggesting the linkage
of the A-allele and increased CRC risk.
In the stratified analyses, the results showed that the association
between the CCND1 G870A polymorphism and CRC risk
remained significant in Caucasians and sCRC but not in Asians
or HNPCC, which supports the hypothesis that genetic back-
grounds and the environment in which patients live in might play
important roles in the development of CRC [5]. Meanwhile, the
finding that no association between the CCND1 genotype and
CRC risk was observed in the comparison model of either the
colon subgroup or the rectum subgroup was in contrast with the
results from another meta-analysis investigating digestive tract
cancers and the risk associated with the CCND1 G870A
polymorphism [50]. We also found a significant association
between G870A and CRC risk in a subset of hospital-based
studies but not in the population-based studies. The lack of proper
matching of controls among the studies might influence the
consistency in our current results.
Meta-analysis is an important tool for revealing trends that
might not be apparent in a single study. The pooling of
Figure 3. The L’Abbe ´ plot [14] for the assessment of CRC risk in
each group (G/A+A/A vs. G/G). Each circle represents individual trial
sizes, and the circles are proportional to the study weights (participant
number). The diagonal dotted line indicates that the CRC risk was equal
in the two arms within the trials. The solid regression line represented a
summary OR of 1.127 (G/A+A/A vs. G/G), which was estimated from the
pooled results of all 22 studies.
doi:10.1371/journal.pone.0036813.g003
Figure 4. Begg’s funnel plot [17] (GA vs. GG) for the identification of publication bias in all studies.
doi:10.1371/journal.pone.0036813.g004
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36813independent but similar studies increases precision and therefore
increases the confidence level of the findings. The current meta-
analysis has some advantages. First, the number of total cases and
controls was substantial, which significantly increased the statistical
power of the analysis. Second, no publication biases were detected,
which indicates that the entire pooled result may be unbiased.
Despite these advantages, some limitations in the current meta-
analysis should be acknowledged. First, the controls were not
uniformly defined. Although most of the patients in the control
groups were selected from healthy populations, some might have
had a benign disease. Therefore, there was a lack of proper
matching, and the results are based on unadjusted estimates. The
current meta-analysis is unable to solve problems with confound-
ing factors that could be inherent in the included studies.
Inadequate control of the confounders might bias the results
either toward exaggeration or underestimation of risk estimates.
Second, stratifying analyses were based on a relatively small
number of studies from which detailed individual data were
available; therefore, some of the subgroup analyses were difficult to
perform. Third, although there is no indication of major
publication bias in the formal evaluation used, potential publica-
tion bias is impossible to completely exclude because small studies
with null results tend to not be published. Finally and mostly
importantly, whether the CCND1 G870A polymorphism is
independently predictive of cancer risk remains controversial
[6,51]. Thus, it should be noted that whether the A allele is a
specific causal variant has yet to be determined. Some functional
studies have demonstrated that the G allele can also produce
transcript b (cyclin D1b), and the A allele can also produce
transcript a (cyclin D1a)[22,51,52]; these results suggest that the A
allele is not universally required for transcript b (cyclin D1b)
production. Furthermore, one study demonstrated that the G870A
and G1722C polymorphisms of cyclin D1 were in linkage
disequilibrium in carcinomas of the head and neck [52]. Another
study demonstrated that there was a synergistic effect between
CCND1 G870A and caspase28 6 n del/ins on CRC [40].
Therefore, it is possible that G870A is in linkage disequilibrium
with another functional variant that modulates cancer risk.
Additionally, there is no genome-wide association study (GWAS)
identifying the susceptibility loci of CCND1 for colorectal cancer,
although one group recently published a GWAS in which CCND1
was strongly suggestive in melanoma carcinogenesis [53]. Hence,
large, prospective, population-based clinical trials and genome-
wide association studies are required to validate the association of
the CCND1 G870A polymorphism with CRC risk.
In conclusion, the current meta-analysis and systematic review
demonstrated that the CCND1 G870A polymorphism is associated
with CRC susceptibility, especially among patients of Caucasian
ethnicity. The current results may prompt further investigation of
diagnostic approaches and prevention strategies to combat CRC.
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